Clinical Trials (Phase III)
Filter News
Found 12,963 articles
-
Celgene is scrapping a late-stage Crohn's disease drug it acquired in a $710M deal three years ago following an interim data analysis.
-
DURECT's Posimir (SABER - Bupivacaine) for post-surgical pain failed its Phase III clinical trial.
-
Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994
10/20/2017
Spero plans for a rapid development approach with SPR994.
-
VBL Therapeutics Announces Orphan Drug Designation for VB-111 in Europe
10/20/2017
The EMA has designated ofranergene obadenovec (VB-111) as an 'orphan medicinal product' for the treatment of ovarian cancer.
-
Omeros Reports Successful OMS721 Treatment of Patient With Both Stem Cell Transplant-Associated Thrombotic Microangiopathy and Graft-Versus-Host Disease
10/20/2017
The results may expand target for Omeros' planned phase 3 program in HCT-TMA.
-
Shionogi Release: Confirmatory Results of the Second Phase 3 Lusutrombopag (S-888711) Study (L-PLUS 2) Presented at the 2017 Liver Meeting of the American Association for the Study of Liver Diseases (AASLD)
10/20/2017
Shionogi announced it will present positive efficacy and safety results from a global Phase 3 study (L-PLUS 2) of lusutrombopag (S-888711), an investigational, once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, at the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting to be held October 20-24 in Washington, D.C.
-
AcelRx's DSUVIA Clinical Trial Results Selected as a Top Abstract for Oral Presentation at ASA's Annual Meeting - ANESTHESIOLOGY 2017
10/20/2017
AcelRx today announced its clinical data presentation on the safety and efficacy of DSUVIA(sufentanil sublingual tablet), 30 mcg classified by age group across four clinical trials at the American Society of Anesthesiologists'(ASA) ANESTHESIOLOGY 2017 Annual Meeting.
-
The company plans to expeditiously advance AMT-061 instead of AMT-060.
-
BioMarin updated the investment community on the Company's development portfolio at R&D Day in New York.
-
Merck's KEYTRUDA (Pembrolizumab) More Than Doubled Median Overall Survival Compared To Chemotherapy After Two Years Of Follow Up In First-Line Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer With High Levels Of PD-L1
10/18/2017
Merck announced the presentation of updated overall survival (OS) findings, a secondary endpoint, from the phase 3 KEYNOTE-024 trial evaluating KEYTRUDA (pembrolizumab).
-
Diffusion Pharma Receives Final FDA Protocol Guidance for Phase III Clinical Trial with TSC in Pa...
10/17/2017
The company expects to begin trial by year-end. -
Immune Design Announces Positive FDA Feedback on Phase III Clinical Trial Design for CMB305 in Synovial Sarcoma Patients
10/17/2017
The company plans to initiate a pivotal Phase 3 trial to support a Biologics License Application for CMB305.
-
Tonix Pharmaceuticals Reports Outcomes From U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya (Cyclobenzaprine HCI Sublingual Tablets) for PTSD
10/17/2017
Tonix is in Phase 3 development of Tonmya, an FDA-designated Breakthrough Therapy for the treatment of PTSD.
-
Cabometyx hit key endpoints of overall survival in its Phase III liver cancer trial and investors are overjoyed.
-
Ionis Pharma released new data from its Phase III NEURO-TTR trial with inotersen in patients with hereditary TTR amyloidosis with polyneuropathy.
-
Follow-up meeting with the FDA is expected before year end.
-
Celsion Announces Publication of the HEAT Study Manuscript in the High Impact Journal, Clinical Cancer Research
10/16/2017
The study was published in Clinical Cancer Research, a high impact, peer-reviewed medical journal.
-
Zogenix's Interim Survey Results Demonstrate Impact on Siblings of Children Suffering from Severe Epilepsy
10/16/2017
Findings Presented by Zogenix at the NORD Rare Diseases and Orphan Products Breakthrough Summit in Washington, D.C.
-
Fennec Announces Positive Results From Phase III SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology 2017 Meeting
10/16/2017
The SIOPEL 6 study met its primary endpoint.
-
Cara Therapeutics Announces Successful End-of-Phase II Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus
10/16/2017
Cara, in consultation with the FDA, has established the key elements of the Phase 3 program to support a New Drug Application (NDA) for I.V. CR845.